Abivax (AAVXF) Payables (2021 - 2026)

Abivax has reported Payables for 6 years, with the latest figure at $34.6 million in Q1 2026.

• On a quarterly basis, Payables fell 45.54% year-over-year to $34.6 million in Q1 2026; TTM through Mar 2026 was $34.6 million, a 45.54% decrease from a year earlier, with the FY2025 full-year figure at $43.7 million, down 13.78% from the prior year.
• Payables was $34.6 million for Q1 2026 at Abivax, down from $43.7 million in the prior quarter.
• The five-year high for Payables was $69.2 million in Q2 2025, with the low at $16.4 million in Q4 2022.
• Average Payables over 5 years is $44.5 million, with a median of $43.7 million recorded in 2025.
• The sharpest annual moves came in 2022 and 2023: Payables tumbled 49.79% in 2022, then soared 210.45% in 2023.
• Over 5 years, Payables stood at $16.4 million in 2022, then jumped by 210.45% to $50.8 million in 2023, then retreated by 0.21% to $50.7 million in 2024, then dropped by 13.78% to $43.7 million in 2025, then fell by 20.95% to $34.6 million in 2026.
• The last three Payables figures came in at $34.6 million (Q1 2026), $43.7 million (Q4 2025), and $35.1 million (Q3 2025), per Business Quant data.